Check your eligibility now & get in touch with a study center

CHECK ELIGIBILITY

ZEUS A research study to see how Ziltivekimab works compared to placebo in patients with cardiovascular disease, chronic kidney disease and inflammation

The purpose of this study is to see if the new study drug, Ziltivekimab, can be used to treat people with cardiovascular disease, chronic kidney disease, and inflammation. The ZEUS study will see if Ziltivekimab can reduce the risk of having cardiovascular events (for example, heart attack and stroke). The term cardiovascular refers to various conditions that affect the heart and blood vessels. These conditions include myocardial infringement (also known as heart attack), cerebrovascular accident (also known as stroke), and peripheral arterial disease (also known as poor circulation). Ziltivekimab is an antibody, which is designed to block the section of IL6 so ziltivekimab can help the body prevent further inflammation.
Am I eligible? Learn More

Detailed Description


Simple Text Block

You can use content blocks to arrange your articles, large texts, instructions. Combine these blocks with media blocks to add illustrations and video tutorials. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links.

Call 1800-9860-568 now to find out if you are eligible.

Age

18 - None

Gender

All

NCT ID

NCT05021835

Phase

3

Status

Recruiting Now

Medical Condition

Inflammation

How is Plaque Psoriasis treated?

Medical Condition

A short sentence to introduce what to expect in the about condition section

Learn more
The Study

A short sentence to introduce what to expect in the about condition section

Learn more
About Clinical Trials

A short sentence to introduce what to expect in the about condition section

Learn more

Your Journey

01
Receiving the medication

You would receive etanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept, as well as study related medical care, is provided at no cost.

02
Visiting the study site

Study participation involves approximately 8 visits to your local study center over 6 to 7 months.

03
Follow-up

There would also be a follow-up telephone call 30days after completing the study. No visits are required after participation is complete.

Call 1800-9860-568 now to find out if you are eligible.